Revenue and Profitability - The company reported a significant reliance on orthokeratology lenses and related products, which currently account for the majority of its sales revenue[5]. - The company's operating revenue for the first half of 2022 was RMB 684,460,891.07, representing a 20.05% increase compared to RMB 570,137,743.19 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was RMB 258,271,355.90, a slight increase of 0.90% from RMB 255,968,022.93 year-on-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 238,754,124.12, reflecting a 13.16% increase from RMB 210,997,096.28 in the previous year[23]. - The main driver for revenue growth was the increasing application of the company's core product, orthokeratology lenses, despite significant impacts from COVID-19 restrictions[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2022, representing a year-on-year growth of 20%[168]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[168]. - The company anticipates a positive cash flow of 200 million RMB by the end of 2022, supporting its growth initiatives and investments[168]. Market Expansion and Product Development - The company is expanding its business into optometry services and comprehensive optometry products to diversify its product structure[6]. - The company is developing its own lens materials, which have passed national performance testing, to mitigate risks associated with imported raw materials[5]. - The company has expanded its production capacity with the addition of two new production lines for lens manufacturing[35]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving product efficiency and user experience[168]. - New product development includes the launch of a next-generation smart lens, expected to contribute an additional 200 million RMB in revenue by Q4 2022[168]. - The company is actively pursuing partnerships and acquisitions to strengthen its market position in the healthcare industry[146]. Financial Performance and Assets - The total assets at the end of the reporting period were RMB 4,662,178,663.65, marking a 56.85% increase from RMB 2,972,426,471.10 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 74.19% to RMB 3,859,696,820.41 from RMB 2,215,832,945.45 at the end of the previous year[23]. - Cash and cash equivalents increased to RMB 2,059,751,753, representing 44.18% of total assets, up from 22.06% in the previous year, due to funds received from issuing shares[54]. - The company reported a significant increase in long-term equity investments, indicating a strategic focus on enhancing control and influence over key subsidiaries[182]. - The company’s total assets amounted to RMB 4,131,562,310.76, compared to RMB 2,460,936,411.05 in the previous year, reflecting a strong asset growth[117]. Risk Management and Legal Considerations - The company faces risks related to the concentration of sales in the East China region, which remains significantly higher than other regions[6]. - The company acknowledges potential legal risks associated with the long-term use of its medical optical devices[5]. - The company is actively managing risks related to increased competition from both domestic and international brands in the orthokeratology lens market[8]. - The company emphasizes a "safety first" approach in its risk management framework, focusing on product quality and user safety[47]. Research and Development - The company emphasizes a strong R&D advantage with a dedicated team that has over 20 years of experience in the rigid contact lens field, supporting continuous innovation and market leadership[40]. - Research and development investment increased by 27.91% to ¥16,992,355.64, compared to ¥13,284,158.18 in the previous year[50]. - The company has obtained 3 invention patents, 1 utility model patent, and 1 design patent related to medical devices during the reporting period[35]. Subsidiaries and Ownership Structure - The company holds a 100% stake in 18 subsidiaries, indicating strong control over its operations[146]. - The company has established a significant number of subsidiaries focused on eye care and medical devices, reflecting its commitment to this sector[147]. - The company has a 51% to 66.25% stake in several subsidiaries, suggesting a diversified investment strategy in the healthcare sector[146]. - The company is expanding its market presence with multiple subsidiaries across various regions, including Qingdao and Yantai[146]. Shareholder and Governance - The company has not declared any cash dividends or stock bonuses for the reporting period[9]. - The company held its annual general meeting on April 20, 2022, with a participation rate of 57.13%[83]. - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[84]. - The total number of shares increased from 850,508,170 to 894,831,756, with an increase of 44,323,586 shares due to a specific issuance[101]. Compliance and Reporting - The financial report for the first half of 2022 was not audited[112]. - The company adheres to the Chinese accounting standards, ensuring that its financial statements accurately reflect its financial position and operational results[159]. - The company has implemented a unified accounting policy for mergers and acquisitions, ensuring consistency in financial reporting across its subsidiaries[160]. Cash Flow and Financing Activities - The net cash flow from operating activities was RMB 266,346,288.44, down by 3.55% from RMB 276,162,123.91 in the same period last year[23]. - The net cash flow from financing activities surged by 934.40% to ¥1,352,905,139.14, primarily due to funds received from issuing shares to specific investors[50]. - Cash inflow from financing activities amounted to ¥1,544,799,788.29, with a net cash flow of ¥1,417,216,654.81, significantly improving from a negative cash flow of -¥130,820,812.94 in the previous year[127].

Financial Performance - The company's revenue for Q1 2022 was ¥371,150,930.09, representing a 29.35% increase compared to ¥286,936,799.16 in Q1 2021[3] - Net profit attributable to shareholders for Q1 2022 was ¥148,100,239.31, a 7.24% increase from ¥138,104,771.92 in the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥137,680,611.82, up 28.66% from ¥107,012,556.45 in Q1 2021[3] - Operating revenue for the current period reached ¥371,150,930.09, an increase of 29.35% compared to the previous period's ¥286,936,799.16[11] - The total revenue for the first quarter of 2022 was approximately 185.84 million CNY, an increase from 167.73 million CNY in the same period last year, representing an increase of about 7.5%[24] - The net profit for the first quarter of 2022 was approximately 163.41 million CNY, compared to 146.94 million CNY in the previous year, reflecting a growth of around 11.2%[24] - Basic earnings per share for the first quarter of 2022 were 0.1744 CNY, up from 0.1629 CNY in the same quarter of the previous year, indicating an increase of approximately 9.2%[25] - The total comprehensive income for the first quarter of 2022 was approximately 163.41 million CNY, compared to 146.94 million CNY in the same period last year, marking an increase of about 11.2%[25] Cash Flow and Investments - The company's cash flow from operating activities for Q1 2022 was ¥158,750,502.59, a slight increase of 0.65% from ¥157,725,436.22 in Q1 2021[3] - Net cash flow from operating activities was ¥158,750,502.59, a slight increase of 0.65% compared to the previous period[12] - Investment activities resulted in a net cash outflow of ¥58,322,480.11, improving from a net outflow of ¥65,086,963.22 in the previous period[12] - Financing activities generated a net cash inflow of ¥17,017,312.57, a significant increase of 656.88% compared to the previous period[12] - The net cash flow from investment activities was -58,322,480.11 CNY, an improvement from -65,086,963.22 CNY in the previous year[27] - Cash inflow from financing activities totaled 51,212,679.20 CNY, significantly higher than 5,332,814.50 CNY in the same period last year[27] - The net cash flow from financing activities was 17,017,312.57 CNY, compared to 2,248,340.18 CNY in the previous year[27] - The company received 48,790,375.20 CNY from investment, a substantial increase from 4,884,815.00 CNY in the previous year[27] Assets and Liabilities - Total assets as of March 31, 2022, were ¥3,184,618,997.44, reflecting a 7.14% increase from ¥2,972,426,471.10 at the end of the previous year[4] - The total liabilities as of March 31, 2022, were CNY 467,767,304.74, compared to CNY 436,351,201.51 at the start of the year[22] - The cash and cash equivalents at the end of the first quarter were CNY 773,129,800.87, up from CNY 655,691,465.82 at the beginning of the year[20] - The inventory level increased to CNY 113,088,305.11 from CNY 105,960,111.58 at the start of the year, indicating a growth of 6.3%[20] - The company reported a significant increase in accounts receivable, which rose to CNY 181,085,437.92 from CNY 155,759,640.48, reflecting a growth of 16.3%[20] Shareholder Information - The company’s major shareholder, Nanjing Otao Information Technology Co., Ltd., holds 14.41% of shares, amounting to 122,790,521 shares[13] - The total number of ordinary shareholders at the end of the reporting period was 64,899[13] Future Plans - The company plans to continue expanding its market presence and investing in new product development[12] - The company has plans for future expansion and product development, although specific details were not provided in the financial report[18] Other Financial Metrics - The weighted average return on net assets for Q1 2022 was 6.46%, down from 7.59% in the same period last year[4] - The company adjusted its idle fund investment structure, resulting in a decrease of approximately ¥4.15 million in investment income compared to the previous year[7] - Financial expenses decreased by 97.18% to ¥57,276.13, attributed to increased interest income from bank deposits[11] - The company reported a 331.89% increase in other income, totaling ¥2,225,743.75, primarily due to increased government subsidies[11] - The company reported investment income of approximately 7.20 million CNY, a significant decrease from 32.77 million CNY in the previous year, indicating a decline of about 78%[24] - The operating profit for the first quarter of 2022 was approximately 185.69 million CNY, compared to 167.59 million CNY in the same period last year, reflecting an increase of about 10.8%[24] Audit and Reporting - The company did not conduct an audit for the first quarter report[28] - The report was officially announced by the board of directors on April 27, 2022[29]

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.295 billion, representing a 48.74% increase compared to ¥870.66 million in 2020[33]. - The net profit attributable to shareholders for 2021 was approximately ¥554.74 million, an increase of 28.02% from ¥433.32 million in 2020[33]. - The net cash flow from operating activities reached approximately ¥630.09 million, marking a 65.41% increase from ¥380.94 million in 2020[33]. - The basic earnings per share for 2021 was ¥0.6536, up 27.21% from ¥0.5138 in 2020[33]. - Total assets at the end of 2021 were approximately ¥2.972 billion, a 34.32% increase from ¥2.213 billion at the end of 2020[33]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥2.216 billion, reflecting a 26.48% increase from ¥1.752 billion at the end of 2020[33]. - The company reported a non-operating income of approximately ¥52.48 million from financial products in 2021, compared to ¥49.10 million in 2020[38]. - The total revenue for 2021 reached ¥1,295,045,844.66, representing a year-on-year increase of 48.74% compared to ¥870,663,602.06 in 2020[70]. - The revenue from the medical sector surged by 180.78% year-on-year, amounting to ¥176,997,439.56, with a gross margin increase of 19.29%[74]. - The sales of orthokeratology lenses increased by 28.45% year-on-year, generating ¥669,915,613.52, although the gross margin slightly decreased by 0.55%[74]. Business Strategy and Expansion - The company plans to distribute a cash dividend of 1.46 RMB per 10 shares, based on a total of 850,508,170.00 RMB[16]. - The company is expanding its business into optometry services and full optometry products to diversify its product structure[11]. - The company plans to continue expanding its market presence and invest in new product development to enhance user experience[28]. - The company is focusing on enhancing production efficiency and capacity to meet growing demand in the orthokeratology lens market[84]. - The company plans to expand its optical service market by establishing joint ventures and self-operated optical terminals in regions with resource advantages, such as Nanjing and Hefei[130]. - The company aims to enhance its brand system by improving product variety and quality management, focusing on both product and service brand development[137]. - The company is expected to continue its growth trajectory with a focus on expanding its service offerings and geographical reach[87]. - The company has established a stable supply relationship with Bausch & Lomb for raw materials and is expanding partnerships with other suppliers to mitigate supply risks[141]. Research and Development - The company has a strong R&D team with over 20 years of experience in the hard contact lens field, holding complete independent intellectual property rights for various related technologies[52]. - The company is developing new products, including high-oxygen-permeable orthokeratology lenses and smart eye care devices, aimed at enhancing product lines and sales revenue[92][93]. - The company has invested in several new product development and medical technology companies, enhancing its position in the eye care industry and laying a solid foundation for high-quality investments[60]. - The company plans to increase investment in research and development, production capacity, quality improvement, and market expansion for rigid contact lenses[128]. - The company's R&D investment in 2021 amounted to ¥27,341,027.67, representing 2.11% of operating revenue, a slight decrease from 2.19% in 2020[95]. Market Risks and Challenges - The company faces risks related to the concentration of sales in the East China region, which still accounts for a significant portion of overall performance[12]. - The company acknowledges potential impacts from national healthcare reforms, particularly if its main products are included in insurance coverage and subject to bulk purchasing[8]. - The company is exposed to risks from fluctuations in gross profit margins due to increasing competition in the orthokeratology lens market[14]. - The company is currently not included in the medical insurance scope, which may affect future sales if policies change[8]. - The sales of orthokeratology lenses fluctuated due to the COVID-19 pandemic, with some regions experiencing temporary declines in business volume due to restrictions on non-emergency medical services[52]. Corporate Governance and Management - The company has established a robust internal control system, ensuring compliance with financial regulations and improving governance standards[153]. - The company has maintained a strong performance in corporate governance, with no unresolved issues reported in compliance with regulatory standards[155]. - The company has a diverse board of directors with backgrounds in engineering, finance, and law, contributing to its strategic decision-making[161]. - The company has a comprehensive compensation system based on performance evaluation, aiming to be competitive within the industry[182]. - The company has established a strong governance framework with independent directors contributing to its strategic oversight[166]. Financial Position and Investments - The company reported a significant increase in financing cash outflow, totaling ¥232,226,152.10, a rise of 339.47% compared to ¥52,842,517.85 in 2020[102]. - The net increase in cash and cash equivalents for 2021 was ¥328,981,203.55, a substantial increase of 204.30% from ¥108,109,892.19 in the previous year[103]. - The company has a total of 12 registration certificates for orthokeratology lenses, with increasing competition from new brands entering the market[43]. - The company has established multiple subsidiaries in 2021, including 12 new investments and 15 mergers under non-same control[87]. - The company has undergone several equity disposals, which may affect its operational structure and financial performance in the upcoming periods[88].

Financial Performance - The company's revenue for Q3 2021 was ¥425,991,350.48, representing a 37.61% increase year-over-year[4] - Net profit attributable to shareholders for Q3 2021 was ¥186,994,921.86, up 25.02% compared to the same period last year[4] - For the first three quarters of 2021, total revenue reached ¥996,129,093.67, a 64.22% increase year-over-year[8] - The net profit attributable to shareholders for the first three quarters was ¥442,962,944.79, reflecting a 59.63% growth compared to the previous year[8] - Total operating revenue for Q3 2021 reached ¥996,129,093.67, a significant increase of 64.2% compared to ¥606,596,719.70 in the same period last year[24] - Net profit for Q3 2021 was ¥476,342,514.11, up 67.2% from ¥284,952,315.46 in Q3 2020[26] - Basic earnings per share increased to ¥0.5222, compared to ¥0.3273 in the previous year, reflecting a growth of 59.5%[27] Cash Flow and Liquidity - The company's cash flow from operating activities for the first three quarters was ¥496,148,435.26, an increase of 95.55% year-over-year[5] - Cash inflows from operating activities totaled ¥1,059,693,636.57, a 68.55% increase from ¥628,714,620.17, mainly due to higher sales revenue and increased collection of receivables[13] - Cash flow from operating activities was ¥1,047,785,061.92, compared to ¥620,699,571.31 in the same period last year, representing a growth of 68.9%[28] - Net cash flow from operating activities reached CNY 496,148,435.26, compared to CNY 253,713,164.64 in the same period last year, indicating a year-over-year increase of 95.5%[29] - The company reported a net increase in cash and cash equivalents of CNY 592,008,683.27, compared to CNY 94,854,467.46 in the previous year, showing a substantial increase of 523.5%[30] Assets and Liabilities - Total assets as of September 30, 2021, were ¥2,848,995,281.08, a 28.74% increase from the end of the previous year[5] - The company's total assets reached ¥2,848,995,281.08, up from ¥2,212,923,975.75, indicating a growth of 28.7%[23] - Total liabilities as of Q3 2021 amounted to ¥458,905,703.20, a 106.7% increase from ¥221,735,346.69 in the same period last year[23] - The company’s total liabilities increased to CNY 243,591,838.24 from CNY 209,819,798.92, reflecting a rise of 16.1%[35] - The total non-current liabilities were CNY 11,915,547.77, reflecting a strategic management of long-term obligations[36] Investment and Growth - Investment income surged by 147.15% to ¥61,245,769.25 from ¥24,780,888.14, attributed to gains from the transfer of subsidiary equity and increased returns from idle funds[12] - The significant increase in investment cash inflow suggests a robust investment strategy and potential for future growth[30] - The company’s long-term equity investments rose to RMB 167.55 million, up from RMB 75.51 million at the end of 2020, marking an increase of approximately 121%[20][21] Research and Development - R&D expenses rose by 51.09% to ¥20,560,255.26 from ¥13,608,300.55, reflecting increased investment in research and development[12] - Research and development expenses for Q3 2021 were ¥20,560,255.26, an increase of 51.1% from ¥13,608,300.55 in Q3 2020[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 44,619, with the largest shareholder holding 35.14% of the shares[14] - The company reported a total of CNY 988,376,516.00 in undistributed profits, contributing to a total equity attributable to shareholders of CNY 1,751,983,461.21[36] Other Financial Metrics - The company experienced a 60.14% increase in income tax expenses, amounting to ¥78,545,205.97, correlating with the rise in profits[12] - The total cost of operations for Q3 2021 was ¥507,492,351.31, which is a 71.6% increase from ¥295,574,405.62 in the previous year[25] - The company has not audited its third-quarter report, which may affect investor confidence in the reported figures[38]

Supply Chain and Raw Materials - The company reported a stable supply relationship with Bausch & Lomb for raw materials, ensuring supply and price stability during the reporting period[2]. - The company is diversifying its raw material suppliers to mitigate risks associated with supplier concentration[55]. - The company maintains a stable supply relationship with Bausch & Lomb for raw materials, ensuring supply and price stability[54]. Financial Performance - The company's revenue for the reporting period reached ¥570,137,743.19, representing a 91.94% increase compared to ¥297,037,401.77 in the same period last year[13]. - Net profit attributable to shareholders was ¥255,968,022.93, a 100.09% increase from ¥127,923,865.88 year-on-year[13]. - The net cash flow from operating activities was ¥276,162,123.91, showing a significant increase of 154.80% compared to ¥108,383,645.95 in the previous year[13]. - Basic earnings per share increased to ¥0.3018, up 98.55% from ¥0.1520 in the same period last year[13]. - Total assets at the end of the reporting period were ¥2,581,263,412.76, reflecting a 16.64% increase from ¥2,212,923,975.75 at the end of the previous year[13]. - The net assets attributable to shareholders increased to ¥1,911,563,210.47, a rise of 9.11% from ¥1,751,983,461.21 at the end of the previous year[13]. - The company achieved operating revenue of ¥570,137,743.19, representing a year-on-year growth of 91.94% and a growth of 117.21% compared to 2019[17]. - Net profit attributable to shareholders reached ¥255,968,022.93, an increase of 100.09% year-on-year and 119.49% compared to 2019[17]. Research and Development - The company is currently in the pilot testing phase for lens material research projects conducted by its R&D center[2]. - The company has established a comprehensive R&D innovation system, focusing on eye health and myopia prevention[22]. - The company has received one utility model patent and one software copyright during the reporting period[22]. - The R&D center's lens material project has entered the pilot verification stage, indicating progress in product development[55]. - Research and development investment rose by 58.53% to ¥13,284,158.18 from ¥8,379,821.72, reflecting the company's commitment to innovation[35]. Market Competition - The competitive landscape includes 7 imported brands and 1 domestic brand for orthokeratology lenses, indicating intensified competition despite market expansion[3]. - The market for orthokeratology technology is expected to grow due to increasing government attention on myopia prevention[19]. - The company is a leading enterprise in the domestic orthokeratology lens segment, with 15 years of industry experience and a wide user base[23]. Product Development and Innovation - The company plans to enhance product competitiveness through regular innovation, personalized services, and marketing support[3]. - The company emphasizes personalized design and production, ensuring timely delivery and stability for custom orders[23]. - The company's orthokeratology lenses allow for a maximum myopia reduction of 600 degrees, exceeding the typical market limit of 500 degrees[23]. - The company has launched several safety auxiliary products, including disinfection boxes for hard lens trial sets and real-time corneal status monitors[31]. Corporate Governance and Shareholder Relations - The company has established a comprehensive governance structure and improved internal management to enhance operational standards and protect shareholder rights[68]. - The company plans to not distribute cash dividends or issue bonus shares for the first half of 2021[64]. - The company granted 512,000 restricted stocks at a price of 33.78 CNY per share to 25 incentive targets as part of its 2020 restricted stock incentive plan[65]. - The company intends to repurchase and cancel 163,828 restricted stocks from various incentive targets as part of its stock incentive plans[66]. Operational Challenges and Risks - The ongoing pandemic may lead to local government restrictions affecting the operation of optical and vision care services, potentially reducing product orders[3]. - The company is facing risks related to changes in national policies on medical device production and operation, which could impact business plans[54]. - The overall financial health remains a concern, with several subsidiaries reporting significant losses, necessitating a strategic review of operations[130]. Expansion and Market Presence - The company has established over 1200 cooperative terminals by adding more than 100 new partners in the first half of 2021[30]. - The company plans to open 50 new retail locations by the end of 2022, aiming for a 15% increase in foot traffic[128]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2022[129]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[131]. Financial Reporting and Compliance - There were no discrepancies between the financial reports prepared under international accounting standards and those under Chinese accounting standards[14]. - The company has maintained a commitment to transparency in financial reporting, adhering to relevant accounting standards and regulations[138]. - The financial statements were prepared based on the assumption of going concern, with no identified issues affecting the company's ability to continue operations for the next 12 months[138]. User Engagement and Community Initiatives - User data indicates a total of 1.5 million active users, representing a 20% increase year-over-year[129]. - The company invested 1 million RMB to develop a digital monitoring system for myopia prevention, which is provided free of charge to educational institutions and hospitals[69]. - A total of 1,052 public welfare activities were conducted, including role-playing and lectures on myopia prevention[69].

Financial Performance - The company's revenue for Q1 2021 reached ¥286,936,799.16, representing a 175.99% increase compared to ¥103,967,367.36 in the same period last year[3] - Net profit attributable to shareholders was ¥138,104,771.92, a significant increase of 263.70% from ¥37,972,256.67 in the previous year[3] - Basic earnings per share rose to ¥0.2280, up 261.33% from ¥0.0631 in the previous year[3] - Operating profit for Q1 2021 was ¥167,592,165.71, a rise of 324.5% compared to ¥39,429,062.17 in the same quarter last year[34] - Net profit for Q1 2021 was ¥146,936,256.90, up 361.5% from ¥31,806,511.68 in Q1 2020[34] Cash Flow - The net cash flow from operating activities surged to ¥157,725,436.22, marking a 1,558.69% increase from ¥9,509,035.89 in the same period last year[3] - The net cash flow from investment activities was negative at -¥65,086,963.22, indicating increased financial management activities[15] - Cash flow from operating activities generated a net amount of CNY 157,725,436.22, compared to CNY 9,509,035.89 in the previous year, indicating a substantial improvement[39] - The total cash inflow from operating activities was CNY 322,330,675.15, compared to CNY 126,077,439.85 in the same quarter last year, reflecting a strong operational performance[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,539,360,687.66, an increase of 14.75% from ¥2,212,923,975.75 at the end of the previous year[3] - The company's total liabilities reached CNY 384,128,529.41, up from CNY 221,735,346.69, reflecting a significant increase of around 73.2%[28] - Current liabilities amounted to CNY 208,198,810.83, slightly down from CNY 209,819,798.92, showing a decrease of approximately 0.8%[28] - Total liabilities increased to ¥255,568,396.54, up 28.6% from ¥198,747,359.50 year-over-year[32] Investments and Expenses - R&D expenses rose to ¥6,933,902.94, a 97.52% increase from the previous year, indicating increased investment in research and development[13] - Investment income surged to ¥32,772,801.42, a 347.71% increase year-over-year, attributed to gains from subsidiary equity transfers and increased financial management returns[12] - The company’s tax expenses increased by 203.64% to ¥20,797,391.07, reflecting higher total profits[12] Shareholder Information - The net assets attributable to shareholders increased to ¥1,898,943,624.81, reflecting an 8.39% rise from ¥1,751,983,461.21 at the end of the previous year[3] - The top shareholder, Tao Yuequn, holds 35.14% of the shares, amounting to 213,493,449 shares[6] Operational Highlights - Major factors driving performance growth included strong product sales, increased revenue from marketing service terminals, effective control of operating expenses, and a rise in corporate income tax deductions[16] - The company completed the first registration of a Class II medical device product, fluorescein sodium ophthalmic test strips, during the reporting period[17] - The company has established long-term supply contracts with its main raw material supplier, Bausch & Lomb, to ensure supply stability[20] Risk Management - The company is addressing risks related to changes in national industry policies and product legal risks by implementing ISO13485 quality management systems and enhancing training and support for users[19] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[36]

Financial Performance - The company's operating revenue for 2020 was ¥870,663,602.06, representing a 34.59% increase from ¥646,903,716.16 in 2019[15]. - The net profit attributable to shareholders for 2020 was ¥433,320,972.58, up 41.20% from ¥306,889,255.38 in 2019[15]. - The net profit after deducting non-recurring gains and losses was ¥397,060,877.13, a 48.60% increase compared to ¥267,205,466.84 in 2019[15]. - The company's total assets at the end of 2020 were ¥2,212,923,975.75, reflecting a 37.79% increase from ¥1,606,021,278.37 at the end of 2019[15]. - The basic earnings per share for 2020 was ¥0.72, which is a 41.18% increase from ¥0.51 in 2019[15]. - The weighted average return on equity for 2020 was 28.18%, up from 26.13% in 2019[15]. - The net cash flow from operating activities for 2020 was ¥380,935,352.57, a 38.34% increase from ¥275,365,341.16 in 2019[15]. - The company reported a quarterly revenue of ¥309,559,317.93 in Q3 2020, contributing to a total annual revenue growth[17]. - The company received government subsidies amounting to ¥6,195,674.69 in 2020, compared to ¥7,495,042.19 in 2019[20]. - The total net assets attributable to shareholders at the end of 2020 were ¥1,751,983,461.21, a 31.69% increase from ¥1,330,428,627.01 at the end of 2019[15]. Dividend Distribution - The company plans to distribute a cash dividend of 0.93 RMB per 10 shares and issue 3.5 bonus shares per 10 shares, along with a capital reserve conversion of 0.5 shares per 10 shares[4]. - The cash dividend represents 20.99% of the total profit distribution amount, reflecting the company's commitment to shareholder returns[101]. - The cash dividend payout ratio for 2020 was 13.04% of the net profit attributable to ordinary shareholders, compared to 13.19% in 2019 and 14.53% in 2018[104]. - The total cash dividends distributed over the last three years amounted to RMB 128,384,175.45, reflecting a consistent return to shareholders[104]. Market and Product Development - The company is actively developing its own lens materials, with progress reported in its R&D center, expected to complete material development soon[3]. - The market for orthokeratology lenses is expanding, but competition is intensifying with new domestic and imported brands entering the market[3]. - The company’s core product, orthokeratology lenses, continues to see rising demand, driven by personalized customization and high correction levels[26]. - The company completed the registration of orthokeratology lenses and the first registration of fluorescein sodium ophthalmic test strips in 2020, with two products entering clinical trials[30]. - The company achieved significant progress in the development of hard lens materials and eye drop solutions for myopia control in 2020, with a new drug production workshop established and approved[30]. - The company launched a new eye drop production line in 2020, with the related hospital obtaining the necessary production license in November 2020[44]. - The company is positioned as a leader in the hard contact lens segment, with a strong focus on myopia prevention among youth[27]. Risk Management - The company acknowledges potential risks from changes in national industry policies and product regulations that could impact its operations[3]. - The company emphasizes the importance of quality management systems, such as ISO13485, to mitigate risks associated with product safety and quality[3]. - The company is focused on reducing risks from concentrated supplier relationships by establishing agreements with alternative suppliers[3]. - The company is addressing risks related to concentrated suppliers by collaborating with alternative suppliers and developing its own lens materials[97]. - The company emphasizes the importance of risk management in response to potential changes in national industry policies and product legal risks, implementing quality management systems to mitigate these risks[96]. Research and Development - The company is committed to ongoing technological training and support for healthcare professionals to ensure high-quality service delivery[3]. - The company invested in multiple R&D firms in 2020, including Hefei Ouz and Shenzhen Smart Eye, enhancing its product and technology range[31]. - The company is in the late-stage development of a new hard contact lens material aimed at reducing external purchases[66]. - A new product, the "Intelligent Hard Lens Cleaning Device," is in the sample trial phase, aimed at enhancing product competitiveness[67]. - The company’s investment in research and development continues to drive innovation, with new products like the intelligent temperature-controlled eye nebulizer in trial[43]. Strategic Expansion - The company plans to expand production capacity by purchasing 40-50 acres of land in Hefei High-tech Zone to build approximately 35,000 square meters of production facilities and 15,000 square meters of R&D space, expected to be completed in two years[94]. - The company aims to maintain its leadership position in the rigid contact lens market, focusing on R&D, production, and sales[92]. - The company plans to enrich its product line by developing all types of rigid lens products and expanding into other health-related products[93]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[119]. - The company aims to increase its online sales channel contribution to 30% of total sales by the end of the next fiscal year[123]. Employee Engagement and Incentives - A total of 36 employees received stock incentives in 2020, enhancing employee motivation and performance[36]. - The company has implemented an employee incentive plan, reflecting its commitment to employee engagement and retention[133]. - The company established a performance evaluation and incentive system linking management compensation to business performance[191]. - The company provides annual training opportunities for employees, focusing on various levels and roles within the organization[189]. Corporate Governance - The company maintains a strong commitment to corporate governance, ensuring compliance with laws and regulations to protect the rights of all shareholders[153]. - The company has established effective communication channels with investors, enhancing transparency and trust through various platforms[153]. - The company has a structured approach to board appointments, ensuring compliance with shareholder approvals[175]. - The company’s board includes members with teaching positions at universities, enhancing its governance and expertise[180]. Subsidiaries and Acquisitions - The company established multiple new subsidiaries, including 德安欧欧康视健康科技有限责任公司 and 九江欧若拉眼镜有限公司, during the period from September to December 2020[16]. - The company completed several mergers, such as 莱州同明中西医结合医院有限公司 and 青岛泽嘉生物技术有限公司, during the fourth quarter of 2020[20]. - The establishment of 济宁市欧普康科医疗科技有限公司 and 济宁市康益视光科技有限公司 reflects the company's strategy to enhance its service offerings in new regions[35]. - The company has been actively investing in new ventures, with multiple investments in medical device companies like 太仓市梦戴维医疗器械有限责任公司 and 福州康视医疗器械有限公司[45]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 15% to 1.725 billion RMB[117]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative technologies in the optical sector[118]. - The company aims to maintain a competitive edge through continuous investment in technology and market expansion initiatives[59].

Financial Performance - The net profit attributable to shareholders of the listed company reached CNY 149,577,242.40, representing a growth of 32.68% year-on-year[3]. - Operating revenue for the period was CNY 309,559,317.93, which is a 39.12% increase compared to the same period last year[3]. - The basic earnings per share for the period was CNY 0.2491, up 32.78% from the previous year[3]. - The net cash flow from operating activities was CNY 145,329,518.69, showing a 22.78% increase year-on-year[3]. - The company reported a significant increase in investment income, reaching CNY 24,780,888.14, although it was down from CNY 28,603,470.08 in the previous year[40]. - The net profit for Q3 2020 reached CNY 145,774,986.68, representing a growth of 41.5% from CNY 102,935,331.69 in Q3 2019[37]. - The company's total operating income for the year-to-date period reached CNY 606,596,719.70, up 25.0% from CNY 484,989,216.96 in the previous year[39]. Assets and Liabilities - The total assets of the company at the end of the reporting period amounted to CNY 2,031,976,960.98, reflecting a 26.52% increase compared to the previous year[3]. - Total liabilities amounted to CNY 238,926,193.47, up from CNY 168,173,666.45, which is an increase of about 42%[28]. - The company's equity attributable to shareholders reached CNY 1,600,114,822.61, compared to CNY 1,330,428,627.01, showing a growth of approximately 20.3%[29]. - Current assets totaled CNY 1,497,302,805.27, up from CNY 1,232,762,731.56, indicating a growth of about 21.5% year-over-year[26]. - The company's total assets increased significantly, with a notable rise in non-current assets due to new long-term asset acquisitions[12]. Shareholder Information - The company reported a total of 28,504 common shareholders at the end of the reporting period[6]. - The largest shareholder, Tao Yuequn, holds 37.13% of the shares, amounting to 225,493,356 shares[6]. Government and Non-Operating Income - The company received government subsidies amounting to CNY 4,717,656.33 during the reporting period[4]. - The company reported a non-operating income of CNY 32,847,647.73 primarily from financial product returns[4]. Investment Activities - The company has engaged in multiple financial products with various partners, indicating a strategy of utilizing idle funds for investment[18]. - The company has several ongoing investments in fixed-income products, with amounts ranging from 500,000 CNY to 4,000,000 CNY, maturing between May 19, 2021, and June 11, 2021[18]. - The company reported a total of 1,500 million in fixed income investments for various projects, including the Changning and Liaocheng municipal infrastructure projects[19]. - The company has allocated 6,000 million to a floating income asset management plan with Huazhang Securities, set to expire on October 9, 2020[19]. - The company is actively managing idle funds, with a focus on fixed income and floating income investment strategies[19]. Research and Development - The company reported a significant increase in research and development expenses, totaling ¥5,228,478.83, compared to ¥3,851,928.21 in the same quarter last year, reflecting a focus on innovation[34]. - Research and development expenses increased to CNY 5,221,978.83, up 38.1% from CNY 3,778,941.91 in the previous year[37]. Cash Flow and Financial Management - The total cash inflow from operating activities was ¥628,714,620.17, up from ¥530,467,571.26, marking a growth of 18.5%[46]. - The net cash flow from operating activities was ¥215,861,911.02, compared to ¥176,794,730.06 in the prior period, indicating an increase of about 22.1%[49]. - The company has not disclosed any cash dividend policies during the reporting period[23]. Compliance and Governance - There were no violations regarding external guarantees during the reporting period[23]. - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[23].

Supply Chain and Risk Management - The company reported a stable supply relationship with its main supplier, Bausch & Lomb, ensuring supply and price stability through long-term contracts[4]. - The company is focused on reducing risks associated with concentrated suppliers by establishing agreements with alternative suppliers[4]. - The company is addressing potential risks from regulatory changes in the medical device industry by implementing a comprehensive quality management system[3]. - The company emphasizes the importance of maintaining high product quality to mitigate safety risks associated with its medical devices[3]. - The company has implemented measures to mitigate risks associated with changes in national industry policies and product safety[68]. Financial Performance - The company's operating revenue for the reporting period was ¥297,037,401.77, representing a 13.17% increase compared to ¥262,477,045.28 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was ¥127,923,865.88, up 9.70% from ¥116,617,406.11 year-on-year[14]. - The net profit after deducting non-recurring gains and losses was ¥111,286,025.45, reflecting a 13.71% increase from ¥97,867,303.51 in the previous year[14]. - The net cash flow from operating activities was ¥108,383,645.95, which is a 19.78% increase compared to ¥90,487,521.34 in the same period last year[14]. - The total assets at the end of the reporting period amounted to ¥1,744,381,023.79, an increase of 8.62% from ¥1,606,021,278.37 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company were ¥1,453,843,542.49, up 9.28% from ¥1,330,428,627.01 at the end of the previous year[14]. - Basic earnings per share for the reporting period were ¥0.2131, a 9.68% increase from ¥0.1943 in the same period last year[14]. - Diluted earnings per share were ¥0.2121, reflecting a 9.27% increase from ¥0.1941 year-on-year[14]. - The weighted average return on equity was 9.14%, down 1.64% from 10.78% in the previous year[14]. Product Development and Innovation - The company plans to enhance product competitiveness through regular innovation, personalized services, marketing support, and potential mergers and acquisitions[4]. - The company is investing in technology training and support to enhance the quality of fitting services provided by doctors[4]. - The company launched new products including a disinfection box for trial lenses and a new generation of antibacterial contact lens cases, enhancing user experience[23]. - The company continues to invest in new product and technology development, with several investment intentions established with tech firms[23]. - The company has maintained its R&D efforts during the pandemic, resulting in the authorization of 3 utility model patents and 7 design patents in the first half of 2020[23]. Market Position and Competition - The market for orthokeratology lenses is expanding, with the company facing competition from 7 imported brands and one domestic brand[4]. - The company has accumulated over 950,000 users for its core product, the DreamVision orthokeratology lens, which is recognized for its effectiveness in myopia control[18]. - The company is the first in mainland China to obtain product registration for orthokeratology lenses, establishing a leading position in the hard contact lens market[20]. - The company has established a comprehensive marketing network with over 900 fitting points and has completed more than 950,000 fittings[29]. Corporate Governance and Shareholder Matters - The company does not plan to distribute cash dividends or issue bonus shares for the current period[4]. - The company’s annual shareholders' meeting had a participation rate of 62.08%[73]. - The company has no significant litigation or arbitration matters during the reporting period[75]. - The company did not engage in any asset or equity acquisitions or sales during the reporting period[77]. - The company has no overdue amounts in its entrusted financial management[59]. Financial Management and Investments - The company has a solid financial condition and sufficient funds, allowing for effective management of idle funds[58]. - The company has a total of 129,385 million RMB in entrusted financial management, with an outstanding balance of 78,770 million RMB as of June 30, 2020[59]. - The company has invested 29,785 million RMB in bank financial products, 65,500 million RMB in broker financial products, 16,000 million RMB in trust financial products, and 17,000 million RMB in other types of financial products[59]. - The company has implemented strict cost control measures during project execution, leading to lower costs than planned and savings in project investment[55]. Subsidiaries and Market Expansion - The company has established multiple new subsidiaries to expand market share, including Hefei Wenhan Oupukan Vision Technology Co., Ltd. and Ma'anshan Ridawei Medical Technology Co., Ltd.[65]. - The company is actively pursuing market expansion with a focus on establishing new clinics and medical technology firms across various provinces[130]. - The company reported a total of 22 new subsidiaries added to the consolidated financial statements during the period, including Hefei Wenhann Ophthalmic Technology Co., Ltd. and Ma'anshan Ridawei Medical Technology Co., Ltd.[133]. Accounting and Financial Reporting - The financial report was approved by the board of directors on August 26, 2020[127]. - The company adheres to the Chinese Accounting Standards, ensuring that financial statements accurately reflect its financial position and operating results[138]. - The company employs a unified accounting policy for mergers and acquisitions, adjusting the book value of acquired assets and liabilities based on the accounting policies of the acquiring company[140]. - The company recognizes investment income based on the cash dividends or profits declared by the investee[188].

Financial Performance - Total revenue for Q1 2020 was ¥103,967,367.36, a decrease of 14.11% compared to ¥121,047,109.63 in the same period last year[3]. - Net profit attributable to shareholders was ¥37,972,256.67, down 24.81% from ¥50,503,031.72 year-on-year[3]. - Basic earnings per share were ¥0.0946, a decline of 24.92% compared to ¥0.1260 in the same period last year[3]. - The company achieved operating revenue of RMB 103,967,367.36, a decrease of 14.11% compared to the same period last year[14]. - Net profit attributable to shareholders was RMB 37,972,256.67, down 24.81% year-on-year, while net profit excluding non-recurring gains and losses was RMB 31,871,566.25, a decrease of 26.18%[14]. - The decline in performance was primarily due to the impact of the COVID-19 pandemic, which halted operations in ophthalmology and optometry services from late January until mid-March[14]. - The company reported a total profit of CNY 38,655,949.85, a decrease of 32% compared to CNY 56,748,202.83 in the previous year[33]. - The net profit for the first quarter was CNY 31,806,511.68, down 32% from CNY 46,750,279.81 year-over-year[33]. - Total comprehensive income for the first quarter was CNY 60,260,498.70, compared to CNY 51,863,970.16 in the previous year, representing an increase of approximately 16.8%[37]. Cash Flow - Net cash flow from operating activities decreased by 78.42% to ¥9,509,035.89 from ¥44,070,819.54 in the previous year[3]. - Cash inflow from operating activities was CNY 126,077,439.85, down from CNY 141,764,313.48, indicating a decrease of about 11.1% year-over-year[38]. - Cash inflow from investment activities totaled CNY 126,860,141.44, a decrease of 75.2% compared to CNY 510,603,285.39 in the previous year[39]. - Net cash flow from investment activities was CNY -35,868,481.55, contrasting with CNY 24,735,285.33 in the prior year, indicating a negative shift[39]. - Cash inflow from financing activities was CNY 13,005,000.00, up from CNY 5,500,000.00, marking an increase of approximately 136.4%[40]. - Net cash flow from financing activities was CNY 10,310,868.76, compared to CNY 5,153,120.85 in the previous year, showing an increase of about 99.5%[40]. - The ending balance of cash and cash equivalents was CNY 202,101,459.85, down from CNY 252,243,389.49, reflecting a decrease of approximately 20%[40]. - The company reported a significant increase in cash paid for purchasing goods and services, amounting to CNY 50,618,379.83, compared to CNY 32,851,863.51 in the previous year, representing a rise of about 54.2%[39]. Assets and Liabilities - Total assets increased by 3.69% to ¥1,665,218,635.48 from ¥1,606,021,278.37 at the end of the previous year[3]. - The company's total assets amounted to approximately ¥1.67 billion, an increase from ¥1.61 billion as of December 31, 2019[25]. - The total liabilities as of March 31, 2020, were CNY 117,254,094.99, compared to CNY 115,911,375.94 at the end of 2019, indicating a slight increase[31]. - The total current liabilities included contract liabilities of CNY 26,047,050.21, reflecting a shift from prepayments[45]. - The company's short-term borrowings remained stable at ¥200,000, unchanged from the previous period[26]. - The company's inventory increased to approximately ¥66.4 million from ¥53.5 million, representing a growth of about 24.1%[25]. - The accounts receivable increased to CNY 59,382,165.25 from CNY 44,181,445.79, representing a growth of about 34.3%[29]. - The company's contract liabilities were recorded at approximately ¥34.1 million, indicating the presence of future revenue obligations[26]. Shareholder Information - The top shareholder, Tao Yuequn, holds 37.15% of the shares, amounting to 150,328,904 shares[6]. - The company reported a total of 14,719 common shareholders at the end of the reporting period[6]. - There were no significant changes in the shareholding structure of the top ten shareholders during the reporting period[7]. Business Strategy and Development - The company plans to expand its business through academic promotion, technical training, and service upgrades for existing products[14]. - Investment in research and development will be strengthened to promote product upgrades and the development of new products[14]. - The company aims to leverage the gradual recovery of ophthalmology services to capture market opportunities and improve performance[14]. - The company is in the registration inspection phase for new hard contact lens products, which include new materials and designs, enhancing product lines and market competitiveness[16]. - The company is developing eye drops aimed at slowing the progression of myopia, currently in the R&D phase, which will enrich the product line and enhance market competitiveness[16]. - The company is in the market promotion phase for smart glasses aimed at preventing myopia in adolescents, which will diversify the product offerings and strengthen market position[16]. - The company is developing new contact lens care products, including specialized lubricants and cleaning solutions, which are in the pre-market promotion phase, enhancing product offerings[16]. - The company has established a long-term supply contract with main raw material suppliers to ensure supply stability and price consistency, while also collaborating with alternative suppliers to mitigate risks[17]. - The company has invested ¥465.46 million in marketing service network construction, with a cumulative investment of ¥22,155.12 million, achieving 72.32% of the planned investment progress[19]. Risk Management - The company is facing risks from intensified competition, with seven imported brands and one domestic brand approved by the National Medical Products Administration, prompting the need for product innovation and marketing support[17]. - The company has implemented measures to manage risks associated with changes in national industry policies and product legal risks, including adherence to ISO13485 quality management systems[17]. - The company’s strategy adjustment was based on the evaluation of the maturity requirements for network points, reducing the need for excessive subsidiary establishment[20]. - The company aims to enhance the efficiency of raised fund utilization while ensuring the safety of the funds[20].